Sunrise completes $11.8 million placement:
This article was originally published in Clinica
Sunrise Technologies International has completed an $11.8 million private placement at $3.50 per share. The Fremont, California-based company will use the funds to help it to gain pre-market approval for laser products for the treatment of hyperopia, to plan the launch of the Sunrise Hyperion LTK system - an office based instrument which uses two rings of laser energy - and to continue product development.
You may also be interested in...
A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.